Neuland Laboratories Limited has submitted a regulatory filing to BSE Limited and the National Stock Exchange of India Ltd regarding the closure of a US Food and Drug Administration (US FDA) inspection.
The disclosure serves as a follow-up to the company's previous letter dated August 14, 2026, which initially informed the exchanges about the US FDA inspection at its Unit 3 manufacturing facility. The facility is located at Gaddapotharam village, Jinnaram, in the Sangareddy District.
The company reports that the US FDA has now issued an Establishment Inspection Report (EIR) for the inspection that was conducted from August 10, 2026, to August 14, 2026. The US FDA has concluded that this inspection is officially 'closed'.
The disclosure, signed by Company Secretary Sarada Bhamidipati, is made specifically under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No financial or operational impact from this inspection closure is quantified in the disclosure.